现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2015年
1期
88-91
,共4页
彭小波%颜芳%王斌%傅强
彭小波%顏芳%王斌%傅彊
팽소파%안방%왕빈%부강
晚期胃癌%化疗%多西他赛%奥沙利铂%替吉奥
晚期胃癌%化療%多西他賽%奧沙利鉑%替吉奧
만기위암%화료%다서타새%오사리박%체길오
advanced gastric cancer%chemotherapy%Docetaxel%Oxaliplatin%S-1
目的：观察多西他赛、奥沙利铂联合替吉奥（ DOS）与替吉奥联合奥沙利铂（ SOX）方案一线治疗晚期胃癌的近期疗效和安全性。方法：回顾性分析71例晚期胃癌患者，根据患者所接受的化疗方案分为DOS组（36例）和SOX组（35例）。DOS组：多西他赛60mg/m2静脉滴注1h，第1天；奥沙利铂100mg/m2静脉滴注3h，第1天；替吉奥胶囊（ S-1）30mg/m2，口服，每日2次，第1-14天，每21天为1个周期。SOX组：奥沙利铂130mg/m2静脉滴注3h，第1天；替吉奥40mg/m2，口服，每日2次，第1-14天，每21天为1个周期。连用2个周期后评价疗效和每个周期观察不良反应。结果：所有患者均可评估疗效，DOS组CR 1例（2.8%），PR 16例（44.4%），SD 10例（27.8%），有效率（RR）为47.2%，疾病控制率（DCR）为75.0%，中位无进展生存期（PFS）4.4个月。SOX组CR患者0例，PR 15例（42.9%），SD 13例（37.1%），有效率为42.9%，疾病控制率为80%，中位无进展生存期4.0个月。两组的客观有效率、疾病控制率及中位无进展生存期差异均无统计学意义（ p>0.05）。化疗主要不良反应为骨髓抑制、胃肠道反应、脱发和周围神经病变。其中，脱发发生率DOS组显著高于SOX组（p<0.001）；I/II级周围神经毒性，SOX组发生率显著高于DOS组（p=0.005）。结论：DOS和SOX化疗方案治疗进展期胃癌疗效相近，不良反应均可耐受。
目的：觀察多西他賽、奧沙利鉑聯閤替吉奧（ DOS）與替吉奧聯閤奧沙利鉑（ SOX）方案一線治療晚期胃癌的近期療效和安全性。方法：迴顧性分析71例晚期胃癌患者，根據患者所接受的化療方案分為DOS組（36例）和SOX組（35例）。DOS組：多西他賽60mg/m2靜脈滴註1h，第1天；奧沙利鉑100mg/m2靜脈滴註3h，第1天；替吉奧膠囊（ S-1）30mg/m2，口服，每日2次，第1-14天，每21天為1箇週期。SOX組：奧沙利鉑130mg/m2靜脈滴註3h，第1天；替吉奧40mg/m2，口服，每日2次，第1-14天，每21天為1箇週期。連用2箇週期後評價療效和每箇週期觀察不良反應。結果：所有患者均可評估療效，DOS組CR 1例（2.8%），PR 16例（44.4%），SD 10例（27.8%），有效率（RR）為47.2%，疾病控製率（DCR）為75.0%，中位無進展生存期（PFS）4.4箇月。SOX組CR患者0例，PR 15例（42.9%），SD 13例（37.1%），有效率為42.9%，疾病控製率為80%，中位無進展生存期4.0箇月。兩組的客觀有效率、疾病控製率及中位無進展生存期差異均無統計學意義（ p>0.05）。化療主要不良反應為骨髓抑製、胃腸道反應、脫髮和週圍神經病變。其中，脫髮髮生率DOS組顯著高于SOX組（p<0.001）；I/II級週圍神經毒性，SOX組髮生率顯著高于DOS組（p=0.005）。結論：DOS和SOX化療方案治療進展期胃癌療效相近，不良反應均可耐受。
목적：관찰다서타새、오사리박연합체길오（ DOS）여체길오연합오사리박（ SOX）방안일선치료만기위암적근기료효화안전성。방법：회고성분석71례만기위암환자，근거환자소접수적화료방안분위DOS조（36례）화SOX조（35례）。DOS조：다서타새60mg/m2정맥적주1h，제1천；오사리박100mg/m2정맥적주3h，제1천；체길오효낭（ S-1）30mg/m2，구복，매일2차，제1-14천，매21천위1개주기。SOX조：오사리박130mg/m2정맥적주3h，제1천；체길오40mg/m2，구복，매일2차，제1-14천，매21천위1개주기。련용2개주기후평개료효화매개주기관찰불량반응。결과：소유환자균가평고료효，DOS조CR 1례（2.8%），PR 16례（44.4%），SD 10례（27.8%），유효솔（RR）위47.2%，질병공제솔（DCR）위75.0%，중위무진전생존기（PFS）4.4개월。SOX조CR환자0례，PR 15례（42.9%），SD 13례（37.1%），유효솔위42.9%，질병공제솔위80%，중위무진전생존기4.0개월。량조적객관유효솔、질병공제솔급중위무진전생존기차이균무통계학의의（ p>0.05）。화료주요불량반응위골수억제、위장도반응、탈발화주위신경병변。기중，탈발발생솔DOS조현저고우SOX조（p<0.001）；I/II급주위신경독성，SOX조발생솔현저고우DOS조（p=0.005）。결론：DOS화SOX화료방안치료진전기위암료효상근，불량반응균가내수。
Objective:To evaluate the efficacy and safety of Docetaxel/S-1/Oxaliplatin( DOS)and S-1/Oxali-platin( SOX)for the treatment of AGC. Methods:In a retrospective study,71 patients with AGC were analyzed. The patients were divided into two groups according to the regimen received:DOS group(36 cases)and SOX group(35 cases). In the DOS group,all patients received oral S-1 30mg/m2 ,twice daily,d1-14 . On d1 of every cycle,Oxalipla-tin 100mg/m2 was administered intravenously,and Docetaxel 60mg/m2 was administered. In the SOX group,all pa-tients received oral S-1 40mg/m2 ,twice daily,d1-14 . On d1 of every cycle,Oxaliplatin 130mg/m2 was administered intravenously,every 21 days. The efficacy and toxicity were evaluated after at least two consecutive courses. Results:All patients were evaluated for efficacy and safety. In the DOS group:CR 1 case(2. 8%),PR 16 cases(44. 4%),SD 10 cases(27. 8%),the response rate(RR)was 47. 2%,disease control rate(DCR)was 75%,and the median pro-gression free survival(PFS)time was 4. 4 months. In the SOX group:CR 0 case,PR 15 cases(42. 9%),SD 13 cases (37. 1%),the RR was 42. 9%,DCR was 80%,and the median PFS time was 4 months. The response rate,disease control rate and the median progression free survival were not significantly different between two groups(p>0. 05).Myelosuppression,gastrointestinal reaction,alopecia and sensory neuropathy were the most common adverse events ob-served in both groups. There were significantly more alopecia in the DOS group than in the SOX group(p<0. 001). There were significantly more sensory neuropathy in the SOX group than in the DOS group(p=0. 005). Conclusion:Both DOS and SOX are effective and well-tolerated for the treatment of advanced gastric cancer.
